Child-Pugh score A within 14 days prior to study entryXx_NEWLINE_xXIf liver cirrhosis is present, patient must have a Child-Pugh A or B (7 points) classification.Xx_NEWLINE_xXPatient with a Child-Pugh score B or CXx_NEWLINE_xXChild-Pugh Score 5 or 6Xx_NEWLINE_xXChild-Pugh score B or C (for cirrhosis patients only)Xx_NEWLINE_xXChild-Pugh score AXx_NEWLINE_xXPatients who have cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosisXx_NEWLINE_xXPatient with a Child-Pugh score B or CXx_NEWLINE_xXCirrhosis with Child-Pugh score > 7Xx_NEWLINE_xXChild-Pugh score A or B7Xx_NEWLINE_xXPatients with chronic liver disease with a Child-Pugh score B or CXx_NEWLINE_xXSevere liver dysfunction (Child-Pugh Class B or C) is not present; andXx_NEWLINE_xXChild Pugh score A5, A6, B7 or B8Xx_NEWLINE_xXChild Pugh score B9 or C10Xx_NEWLINE_xXChild-Pugh Score class AXx_NEWLINE_xXChild-Pugh class AXx_NEWLINE_xXPatient with a Child-Pugh score B or CXx_NEWLINE_xXChild-Pugh score of AXx_NEWLINE_xXChilds-Pugh cirrhotic status A or B with a maximum score of 7Xx_NEWLINE_xXPatient with a Child-Pugh score B or CXx_NEWLINE_xXBaseline severe hepatic impairment (Child-Pugh Class B & C)Xx_NEWLINE_xXCurrently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the Child Pugh classification)Xx_NEWLINE_xXChild Pugh B or C stage liver diseaseXx_NEWLINE_xXChild Pugh B or C diseaseXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXPatients with liver disease classified as Child Pugh class A or B, with score =< 9Xx_NEWLINE_xXOngoing chronic alcohol consumption or cirrhosis with Child-Pugh score B or C. Known Gilbert disease.Xx_NEWLINE_xXCOHORT B, GROUP 6: HEPATOCELLULAR CARCINOMA: Child-Pugh score > 7Xx_NEWLINE_xXDocumented Child-Pugh score of B or C for hepatocellular carcinoma patients with known underlying liver dysfunctionXx_NEWLINE_xXChronic liver disease, Child-Pugh class B or CXx_NEWLINE_xXHepatic impairment Child-Pugh < B7.Xx_NEWLINE_xXChild-Pugh score AXx_NEWLINE_xXChild-Pugh score of A. A score of B7 is allowed without severe ascites or without hepatic encephalopathy.Xx_NEWLINE_xXPatients with moderate or severe liver impairment, as defined by a Child-Pugh class of B or CXx_NEWLINE_xXCRITERIA SPECIFIC FOR COHORT #2 (MCL): Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXChild Pugh A score 5 or 6 liver functionXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXChilds Pugh A (5-6 points)Xx_NEWLINE_xXImpaired liver function Child-Pugh class B or C (score 7-15).Xx_NEWLINE_xXBaseline moderate and severe hepatic impairment (Child Pugh class B & C)Xx_NEWLINE_xXSubjects must have a Child-Turcotte-Pugh (CTP) score =< 7 to be eligibleXx_NEWLINE_xXChild-Pugh class B and C liver failureXx_NEWLINE_xXSubjects with child Pugh B or C cirrhosis; patients with child Pugh A cirrhosis will be excluded from the dose escalation portion of the trial but can be included in the dose expansion portion of the trial with one dose reduction from the established doseXx_NEWLINE_xXChild-Pugh score of AXx_NEWLINE_xXSevere hepatic impairment (Child-Pugh Class C).Xx_NEWLINE_xXSubjects with severe hepatic insufficiency Child-Pugh score > 6Xx_NEWLINE_xXChild-Pugh scores 5-7Xx_NEWLINE_xXObtained with 21 days of registration: Child Pugh class A (5-6 points) or B (7 points)Xx_NEWLINE_xXChild Pugh class B (8,9) and class C are excluded.Xx_NEWLINE_xXIf patient has underlying cirrhosis, only Child-Pugh classification group A patients should be included in this study; clinical assessment of ascites and encephalopathy is required; Child-Pugh classification must be determined for all study participants at the time of eligibility analysis; as albumin and prothrombin time (PT)/international normalized ratio (INR) are required for Child-Pugh classification; these labs should be drawn with other labs required for eligibility analysisXx_NEWLINE_xXPatients with cirrhosis and severe synthetic liver dysfunction (Child Pugh B-C)Xx_NEWLINE_xXChild-Pugh class-A liver functionXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification.Xx_NEWLINE_xXChild Pugh class A (score = 5 or 6) cirrhosis (assessed within 14 days of SBRT)Xx_NEWLINE_xXPatients with Child Pugh B or C liver failure will be excludedXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXSubject with a Child-Pugh score B or C.Xx_NEWLINE_xXPatient with a Child-Pugh score B or CXx_NEWLINE_xXSubjects with chronic liver disease with hepatic impairment Child-Pugh class B or CXx_NEWLINE_xXChild-Pugh class A or B7 liver functionXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class A, B or C according to the Child Pugh classificationXx_NEWLINE_xXPatients with baseline moderate to severe hepatic impairment (Child-Pugh class B and C)Xx_NEWLINE_xXObtained =< 14 days prior to registration: If baseline liver disease, Child Pugh score not exceeding class AXx_NEWLINE_xXHepatic impairment:\r\n* Phase I: any currently active, clinically significant hepatic impairment (Child-Pugh class A, B, or C according to the Child Pugh classification)\r\n* Phase II: currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXChild Pugh class B or greater hepatic dysfunctionXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXChild-Pugh A or B7Xx_NEWLINE_xXBaseline moderate or severe hepatic impairment (Child-Pugh class B or C)Xx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXHave a Child-Pugh A liver score within 7 days of first dose of study drugXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXChild-Pugh cirrhotic status A or B with a score of 7Xx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXUnderlying hepatic cirrhosis with Child-Pugh class B9 or CXx_NEWLINE_xXChild Pugh class B & CXx_NEWLINE_xXIf liver cirrhosis is present, patient must have a Child-Pugh A/B7 classificationXx_NEWLINE_xXPatients with severe chronic liver disease (Child-Pugh score > 10)Xx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXPatients with a Child-Pugh score less than 6 or greater than 9 for radiation naive patients with cirrhosis (cohort 1)Xx_NEWLINE_xXChild-Pugh score of greater than 6 for patients with cirrhosis who previously received liver directed radiation (EBRT or Y90 RE) (cohort 3)Xx_NEWLINE_xXChild-Pugh score 8 or greaterXx_NEWLINE_xXPatient with a Child-Pugh score B or CXx_NEWLINE_xXSeveral hepatic impairments, define as Child-Pugh Class C or worseXx_NEWLINE_xXChild-Pugh class A or B7 without ascitesXx_NEWLINE_xXChild-Pugh score of AXx_NEWLINE_xXPatients must NOT have liver disease such as cirrhosis or sever hepatic impairment as defined by Child-Pugh class B or CXx_NEWLINE_xXChild-Pugh score must be A to B7.Xx_NEWLINE_xXMust have Child-Pugh A or B liver diseaseXx_NEWLINE_xXChild-Pugh C liver functionXx_NEWLINE_xXChild Pugh class C hepatic dysfunctionXx_NEWLINE_xXSubject has hepatic decompensation (Child-Pugh score > 6 [class B and C])Xx_NEWLINE_xXHave Child B/C cirrhosisXx_NEWLINE_xXThe Child Pugh score must be 5 or 6 (Child Pugh class A)Xx_NEWLINE_xXNo evidence of cirrhosis or cirrhosis grade of Child-Pugh class A or B7Xx_NEWLINE_xXPatients with Child-Pugh A and Child-Pugh B7 (if due to low albumin but not elevated international normalized ratio [INR] or bilirubin) cirrhosis are allowed; Child-Pugh Turcot (CPT) Classification System score will be based upon INR, total bilirubin and serum albumin, as well as the presence/absence of ascites and hepatic encephalopathyXx_NEWLINE_xXChild-Pugh B (except Child-Pugh B7 due to low albumin) or Child-Pugh C cirrhosisXx_NEWLINE_xXChild Pugh score A or BXx_NEWLINE_xXChild-Pugh status CXx_NEWLINE_xXCirrhosis classified as Child-Pugh Class B (Appendix C).Xx_NEWLINE_xXChild-Pugh Class A or C cirrhosis, or hepatic encephalopathy.Xx_NEWLINE_xXChild-Pugh Class A without either current encephalopathy or ascites.Xx_NEWLINE_xXChild-Turcotte-Pugh Classification A or BXx_NEWLINE_xXHepatic cirrhosis or a Child-Pugh score of C (severe hepatic impairment) at the time of randomization.Xx_NEWLINE_xXBaseline moderate or severe hepatic impairment (Child Pugh class B & C)Xx_NEWLINE_xXPatients with Child-Pugh Class B or C cirrhosis or with evidence of portal hypertension by history, endoscopy, or radiologic studies.Xx_NEWLINE_xXChild-Pugh Class AXx_NEWLINE_xXSubjects with chronic liver disease with hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXCirrhotic status of Child-Pugh class A or BXx_NEWLINE_xXHepatic impairment which is moderate (Child-Pugh B) or severe (Child-Pugh C)Xx_NEWLINE_xXChild-Pugh score AXx_NEWLINE_xXLiver function status Child-Pugh (CP) Class A. CP status should be calculated based on clinical findings and laboratory results during the screening period.Xx_NEWLINE_xXAdequate hepatic function for squamous cell NSCLC patients, as defined per protocol. For HCC patients: Child-Pugh score ?6 and Model for End-Stage Liver Disease (MELD) score?15Xx_NEWLINE_xXAdequate hepatic function for squamous cell NSCLC patients, as defined per protocol. For HCC patients: Child-Pugh score ?6 and Model for End-Stage Liver Disease (MELD) score?15Xx_NEWLINE_xXLiver disease with Child-Pugh class B or C liver dysfunctionXx_NEWLINE_xXCirrhosis of any Child Pugh classXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXHas hepatic decompensation (Child-Pugh score > 6; = class B and C)Xx_NEWLINE_xXHCC patients only: Child Pugh class A or B7 liver diseaseXx_NEWLINE_xXMust have Child-Turcotte-Pugh (CTP) A or B7Xx_NEWLINE_xXPatient with severe liver impairment (Child Pugh score B/C)Xx_NEWLINE_xXSevere hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXARM B: Child Pugh Score AXx_NEWLINE_xXSubjects with known hepatic insufficiency (i.e. Child-Pugh score A [mild], Child-Pugh score B [moderate] or Child-Pugh score C [severe]) according to Child-Pugh criteriaXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classificationXx_NEWLINE_xXPatient with a Child-Pugh score B or CXx_NEWLINE_xXPatient with a Child-Pugh score B or C (for cirrhosis patients only)Xx_NEWLINE_xXSubject is classified into Child-Pugh class CXx_NEWLINE_xXChild-Pugh score of A or B with =< 7 points and meeting laboratory eligibility for all parametersXx_NEWLINE_xXChild-pugh B or C cirrhosis.Xx_NEWLINE_xXPatients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic and/or moderate (creatinine clearance [CrCl] 30-50 mL/min) renal impairmentXx_NEWLINE_xXHas a Child-Pugh Class A liver score within 7 days of first dose of study drug.Xx_NEWLINE_xXChild-Pugh Score of A.Xx_NEWLINE_xXPatients with Child pugh score B or CXx_NEWLINE_xXcirrhosis at a level of Child-Pugh B (or worse)Xx_NEWLINE_xXCirrhosis with Child-Pugh score of B or CXx_NEWLINE_xXPatients with Child-Pugh A-C liver diseaseXx_NEWLINE_xXSubject is classified into Child-Pugh class CXx_NEWLINE_xXSubject has Child-Pugh score of ?6, i.e., Child-Pugh A (Appendix 2);Xx_NEWLINE_xXPatient with a Child-Pugh score B or CXx_NEWLINE_xXChild-Pugh Class AXx_NEWLINE_xXDose Escalation Phase: Child-Pugh score of 7 points or less. Cohort 5: Child-Pugh Class B (B7-B8). For all other cohorts Child-Pugh score of 6 points or lessXx_NEWLINE_xXModerate or severe hepatic impairment defined as Child-Pugh class B or CXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child-Pugh classificationXx_NEWLINE_xXPatients with hepatocellular carcinoma may be eligible provided they have total bilirubin ? 3.0 x ULN and are considered Child-Pugh Class A or Child-Pugh Class B7 (Child-Pugh Class B with a total Child-Pugh score not to exceed 7).Xx_NEWLINE_xXCurrently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the NCI/Child Pugh classification)Xx_NEWLINE_xXChild Pugh score ? 7 pointsXx_NEWLINE_xXHave a history of or have current hepatic encephalopathy of any grade, or ascites of Grade >1, or cirrhosis with Child-Pugh Stage B or higher.Xx_NEWLINE_xXHas a Child-Pugh Class A liver score within 7 days of first dose of study drugXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXcirrhosis at a level of Child-Pugh B (or worse) orXx_NEWLINE_xXChild-Pugh score AXx_NEWLINE_xXPatients with liver disease Child Pugh classification B and C.Xx_NEWLINE_xXChild-Pugh score of 10-15 (Class C)Xx_NEWLINE_xXPatient with Child-Pugh score B or CXx_NEWLINE_xXPreserved liver function (Child-Pugh class A or B)Xx_NEWLINE_xXChildâ€™s class CXx_NEWLINE_xXPatients with Child Pugh class B or C hepatic cirrhosisXx_NEWLINE_xXChild Pugh score =< 10Xx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXSubject has hepatic function status of Child Pugh Class A at Screening.Xx_NEWLINE_xXSubject has status of Child-Pugh Class B or C at Screening.Xx_NEWLINE_xXModerate or severe hepatic impairment, i.e. Child-Pugh class B or C.Xx_NEWLINE_xXSevere hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXSubjects with currently active, clinically significant hepatic impairment (> moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classification)Xx_NEWLINE_xXChild Pugh B and CXx_NEWLINE_xXPatient must not have currently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the NCI/Child Pugh)Xx_NEWLINE_xXSevere hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXLiver cirrhosis ? Child-Pugh class B with uncontrolled ascitesXx_NEWLINE_xXSevere hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXChild-Pugh class AXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classificationXx_NEWLINE_xXCirrhosis grade of Child-Pugh class A; Child-Pugh status should be calculated based on clinical findings and laboratory results during the screening periodXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classification)Xx_NEWLINE_xXIf liver cirrhosis is present, patient must have a Child-Pugh A/B7 classificationXx_NEWLINE_xXChild-Pugh score =< 7 (Child A-B)Xx_NEWLINE_xXNon-cirrhotic or no more than Child-Pugh A cirrhosisXx_NEWLINE_xXChild-Pugh liver function class AXx_NEWLINE_xXNo cirrhosis or Child-Pugh A (Child-Turcotte-Pugh [CTP] score < 7) cirrhosisXx_NEWLINE_xXChild-Pugh B or C cirrhosis (CTP score >= 7)Xx_NEWLINE_xXLiver function status Child-Pugh Class A. Child Pugh status should be calculated based on clinical findings and laboratory results during the screening period. Local or loco-regional therapy of intrahepatic tumor lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed >/=4 weeks before first dose of study medication. Note: patients who received sole intrahepatic intraarterial chemotherapy, without lipiodol or embolizing agents are not eligible.Xx_NEWLINE_xXChild Pugh score =< 10Xx_NEWLINE_xXChild-Pugh Stage: A or B7 for Parts A & B, A for Part C, and DXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classificationXx_NEWLINE_xXIf cirrhosis, Child-Pugh classification A or BXx_NEWLINE_xXSystemic disease that would prevent study treatment (uncontrolled hypertension, cardiovascular renal, hepatic (including Child-Pugh Class B and C) or metabolic disease)Xx_NEWLINE_xXChild-Pugh Class A or B.Xx_NEWLINE_xXPatients with Child-Pugh B or C hepatic impairmentXx_NEWLINE_xXSubject has Child-Pugh score of less than 7 (ie, class A or better) with neither encephalopathy nor clinically significant ascites (ascites requiring paracentesis within 3 months of signing the ICF is excluded). Child-Pugh status is calculated based on clinical findings and laboratory results during the screening period.Xx_NEWLINE_xXSerum albumin of at least 2.8 g/dL Note: Laboratories in combination must still be Child Pugh score less than 7 Other laboratory parameters:Xx_NEWLINE_xXHepatic impairment (Child Pugh classes A-C) that is not considered to be the result of leukemic involvement as determined by the PIXx_NEWLINE_xXDecompensated liver disease (Child-Pugh score > 6) or active or past auto-immune hepatitisXx_NEWLINE_xXModerate and severe hepatic impairment, ie Child-Pugh B or CXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment (? moderate hepatic impairment according to the Child Pugh classification).Xx_NEWLINE_xXPatients with severe hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXPatients with severe hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXChild Pugh Class A diseaseXx_NEWLINE_xXChild Pugh AXx_NEWLINE_xXFor patients with hepatocellular carcinoma only, Child-Pugh Class A (score 5-6) disease. Score for hepatic encephalopathy must be 1; the score for ascites must be no greater than 2 and clinically irrelevant; for the determination of the Child-Pugh Class.Xx_NEWLINE_xXPatients with cirrhosis classed as Child-Pugh B or C.Xx_NEWLINE_xXChild-Pugh class A with no clinically apparent ascitesXx_NEWLINE_xXSevere hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXModerate or severe hepatic impairment, i.e. Child-Pugh class B or CXx_NEWLINE_xXHave liver cirrhosis with a Child-Pugh Stage of B or C.Xx_NEWLINE_xXChild-Pugh class of AXx_NEWLINE_xXSevere hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXChild-Pugh Class B and C.Xx_NEWLINE_xXModerate or severe hepatic impairment, i.e. Child-Pugh class B or CXx_NEWLINE_xXPatients with impaired hepatic function as defined by Childs-Pugh class B or CXx_NEWLINE_xXIf patient has underlying cirrhosis, only Child-Pugh classification Group A patients may be included in the resectable cohort of this study; for patients with unresectable disease, Child-Pugh classification Groups A and B are allowed; clinical assessment of ascites and encephalopathy is required; Child-Pugh classification must be determined for all study participants at the time of eligibility analysis; note albumin and prothrombin time (PT)/international normalized ratio (INR) are required for Child-Pugh classification; these laboratories (labs) should be drawn with the other labs required for eligibility analysisXx_NEWLINE_xXHepatic function with a score of < 7 points according to the Child-Pugh SystemXx_NEWLINE_xXCurrently active, clinically significant hepatic impairment >= moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classificationXx_NEWLINE_xXSubjects with impaired hepatic function will be grouped according to Child-Pugh classification scoreXx_NEWLINE_xXChild Pugh Class A liver function scoreXx_NEWLINE_xXCirrhotic status of Child-Pugh grade A. Child-Pugh status should be determined based on clinical findings and laboratory data during the screening period (Appendix B). Subjects on anti-coagulants are to receive 1 point for their INR status, as they are presumed to have a <1.7 baseline PT/INR.Xx_NEWLINE_xXChild-Pugh Classification A (see Appendix D)Xx_NEWLINE_xXChild-Pugh Score A (5-6)Xx_NEWLINE_xXModerate or severe hepatic impairment, i.e. Child-Pugh class B or CXx_NEWLINE_xXModerate and severe hepatic impairment, i.e. Child-Pugh B or CXx_NEWLINE_xXLiver disease such as cirrhosis or severe hepatic impairment (Child-Pugh Class C).Xx_NEWLINE_xXChild-Pugh B-C cirrhotic status based on clinical findings and laboratory resultsXx_NEWLINE_xXMust be Child-Pugh class A a. Patients with uncontrolled massive ascites or presence of hepatic encephalopathy are excludedXx_NEWLINE_xXSignificant liver dysfunction determined as Child-Pugh score B or CXx_NEWLINE_xXPatients with severe hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXPatients with chronic hepatitis and/or cirrhosis are eligible, but must be Child-Pugh class AXx_NEWLINE_xXChild-Pugh class B or C hepatic impairmentXx_NEWLINE_xXChild Pugh class A or B7 liver diseaseXx_NEWLINE_xXIf liver cirrhosis is present, patient must have a Child-Pugh A or B (7 points) classificationXx_NEWLINE_xXECOG PS 0 or 1; Child-Pugh Cirrhotic Status A or B with a score of 7;Xx_NEWLINE_xXChild-Pugh Class A.Xx_NEWLINE_xXcirrhosis at a level of Child-Pugh B (or worse) orXx_NEWLINE_xXHas cirrhosis at a level of Child-Pugh B (or worse), or cirrhosis and a history of hepatic encephalopathy, or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesisXx_NEWLINE_xXHistory of cirrhosis of the liver based on the Child-Pugh score of Class B or C are not eligible to participate. (Appendix B.)Xx_NEWLINE_xXChild-Pugh Class A in the absence of hepatoencephalopathy or clinically evident ascitesXx_NEWLINE_xXHepatic function with a score of 7-9 points according to the Child-Pugh SystemXx_NEWLINE_xXChild Pugh class A liver function or class B7Xx_NEWLINE_xXPatients with Child Pugh liver function worse than B7Xx_NEWLINE_xXNo severe hepatic impairment (Child-Pugh class C) or acute liver diseaseXx_NEWLINE_xXPatients with severe hepatic dysfunction (Child Pugh class C)Xx_NEWLINE_xXModerately impaired hepatic function (Child-Pugh B) or severe hepatic impairment (Child-Pugh C)Xx_NEWLINE_xXSevere hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXSevere hepatic disease, defined as a diagnosis of Child-Pugh Class B or C hepatic disease.Xx_NEWLINE_xXSubjects with severe hepatic insufficiency (Child Pugh score > 9)Xx_NEWLINE_xXSevere liver impairment (Child-Pugh score > 9)Xx_NEWLINE_xXChild-Pugh Score of up to B7Xx_NEWLINE_xXChild-Pugh score of up to B7Xx_NEWLINE_xXChild-Pugh score AXx_NEWLINE_xXChild-Pugh category AXx_NEWLINE_xXChild-Pugh score <7 (Child-Pugh Class A).Xx_NEWLINE_xXIndividuals with a clinical diagnosis fibrosis or cirrhosis of the liver (no more than Child-Pugh classification A; Child-Pugh-Turcotte score of 6 or less) who have:\r\n* An indication for surgical liver resection, OR\r\n* A clinical liver biopsy (with research tissue specimens available for analysis) =< 3 months prior to pre-registrationXx_NEWLINE_xXEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Currently active, clinically significant hepatic impairment (Child-Pugh class B or C)Xx_NEWLINE_xXChild-Pugh class B and C liver failureXx_NEWLINE_xXPatients with severe hepatic impairment (Child-Pugh class C)Xx_NEWLINE_xXChilds-Pugh Class C cirrhosisXx_NEWLINE_xXKnown cirrhosis diagnosed with Child Pugh class A or higher liver diseaseXx_NEWLINE_xXChild Pugh A or BXx_NEWLINE_xXChild-Pugh A/BXx_NEWLINE_xXModerate or severe hepatic insufficiency Child-Pugh score > 6Xx_NEWLINE_xXChild-Pugh liver function Class B or C.Xx_NEWLINE_xXChild-Pugh score ? 6Xx_NEWLINE_xXChild Pugh C cirrhosis or other significant comorbid conditionsXx_NEWLINE_xX